Current management of hepatitis B virus infection before and after liver transplantation

Liver International

Volumn 29, Issue 9, 2009, Pages 1294-1305

  Papatheodoridis, George V ^a   Cholongitas, Evangelos ^b   Archimandritis, Athanasios J ^a   Burroughs, Andrew K ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Entecavir; Hepatitis B; Immunoglobulin; Lamivudine; Liver transplantation; Tenofovir

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ENTECAVIR; HEPATITIS B ANTIBODY; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA; TELBIVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; VIRUS DNA; ANTIVIRUS AGENT; HEPATITIS B HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN;

ANTIVIRAL RESISTANCE; CROSS RESISTANCE; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; HEPATITIS B; HEPATITIS B VIRUS; HOSPITAL ADMISSION; HUMAN; IMMUNOPROPHYLAXIS; KIDNEY DISEASE; LIVER CIRRHOSIS; LIVER FUNCTION; LIVER TRANSPLANTATION; PATIENT MONITORING; PATIENT SELECTION; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PROPHYLAXIS; RECURRENT INFECTION; REVIEW; RISK ASSESSMENT; SURVIVAL RATE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; POSTOPERATIVE COMPLICATION; RECURRENT DISEASE;

ANTIVIRAL AGENTS; DNA, VIRAL; HEPATITIS B; HUMANS; IMMUNOGLOBULINS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; RECURRENCE;

EID: 70449715760     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2009.02085.x     Document Type: Review

References (119)

1. Maddrey W.C. Hepatitis B: an important public health issue. J Med Virol 2000; 61: 362-6.
2. Todo S, Demetris AJ, Van Thiel D, et al. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology 1991; 13: 619-26.
3. O'Grady JG, Smith HM, Davies SE, et al. Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications. J Hepatol 1992; 14: 104-11.
4. Davies SE, Portmann BC, O'Grady JG, et al. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology 1991; 13: 150-7.
5. Samuel D, Muller R, Alexander G, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329: 1842-7.
6. Papatheodoridis GV, Sevastianos V, Burroughs A.K. Prevention of and treatment for hepatitis B virus infection after liver transplantation in the nucleoside analogues era. Am J Transpl 2003; 3: 250-8.
7. Villeneuve JP, Condreay LD, Willems B, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000; 31: 207-10.
8. Kapoor D, Guptan RC, Wakil SM, et al. Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis. J Hepatol 2000; 33: 308-12.
9. Manolakopoulos S, Karatapanis S, Elefsiniotis J, et al. Clinical course of lamivudine monotherapy in patients with decompensated cirrhosis due to HBeAg negative chronic HBV infection. Am J Gastroenterol 2004; 99: 57-63.
10. Papatheodoridis GV, Manolakopoulos S, Dusheiko G, Archimandritis A.J. Therapeutic strategies in the management of patients with chronic hepatitis B. Lancet Infect Dis 2008; 8: 167-78.
11. Papatheodoridis GV, Dimou E, Laras A, et al. Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology 2002; 36: 219-26.
12. Merle P, Trepo C. Therapeutic management of hepatitis Brelated cirrhosis. J Viral Hepat 2001; 8: 391-9.
13. Rosenau J, Bahr MJ, Tillmann HL, et al. Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection. J Hepatol 2001; 34: 895-902.
14. Zimmerman MA, Ghobrial RM, Tong MJ, et al. Antiviral prophylaxis and recurrence of hepatocellular carcinoma following liver transplantation in patients with hepatitis B. Transpl Proc 2007; 39: 3276-80.
15. Samuel D. Liver transplantation and hepatitis B virus infection: the situation seems to be under control, but the virus is still there. J Hepatol 2001; 34: 943-5.
16. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAgnegative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131: 1743-51.
17. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 808-16.
18. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348: 800-7.
19. Tan J, Lok A.S. Antiviral therapy for pre- and post-liver transplantation patients with hepatitis B. Liver Transpl 2007; 13: 323-6.
20. Schiff E, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl 2007; 13: 349-60.
21. Lok ASF, McMahon B.J. Chronic hepatitis B. Hepatology 2007; 45: 507-39.
22. Tenney D, Pokorowski KA, Rose RE, et al. Entecavir at five years shows long-term maintenance of high genetic barrier to hepatitis B virus resistance. Hepatol Int 2008; 2: S77.
23. Schiff E, Simsek H, Lee WM, et al. Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis. Am J Gastroenterol 2008; 103: 2776-83.
24. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-42.
25. Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357: 2576-88.
26. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359: 2442-55.
27. Heathcote EJ, Gane EJ, deMan RA, et al. Two year tenofovir disoproxil fumarate (TDF) treatment and adefovir dipivoxil (ADV) switch data in HBeAg-positive patients with chronic hepatitis B (study 103), preliminary analysis. Hepatology 2008; 48(Suppl.): 376A.
28. Marcellin P, Buti M, Krastev Z, et al. Two year tenofovir disoproxil fumarate (TDF) treatment and adefovir dipivoxil (ADV) switch data in HBeAg-negative patients with chronic hepatitis B (study 102), preliminary analysis. Hepatology 2008; 48(Suppl.): 370A.
29. Van Bommel F, de Man R, Stein K, et al. A multicenter analysis of antiviral response after one year of tenofovir mono-therapy in HBV-monoinfected patients with prior nucleos(t)ide analog experience. J Hepatol 2008; 48(Suppl. 2): S32.
30. Taltavull TC, Chahri N, Verdura B, et al. Successful treatment with tenofovir in a child C cirrhotic patient with lamivudine-resistant hepatitis B virus awaiting liver transplantation. Post-transplant results. Transpl Int 2005; 18: 879-83.
31. Bartholomeusz A, Locarnini S.A. Antiviral drug resistance: clinical consequences and molecular aspects. Semin Liver Dis 2006; 26: 162-70.
32. Murray KF, Carithers RL Jr. AASLD practice guidelines: evaluation of the patient for liver transplantation. Hepatology 2005; 41: 1407-32.
33. Fontana RJ, Keeffe EB, Carey W, et al. Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B. Liver Transpl 2002; 8: 433-9.
34. Fontana RJ, Hann HW, Perrillo RP, et al. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology 2002; 123: 719-27.
35. Zoulim F, Radenne S, Ducerf C. Management of patients with decompensated hepatitis B virus association cirrhosis. Liver Transpl 2008; 14(Suppl. 2): S1-7.
36. Fontana RJ, Lok A.S. Lamivudine treatment in patients with decompensated hepatitis B cirrhosis: for whom and when? J Hepatol 2000; 33: 329-32.
37. Lake J. Do we really need long-term hepatitis B hyperimmune globulin?What are the alternatives? Liver Transpl 2008; 14: S23-26.
38. Shouval D, Samuel D. Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review. Hepatology 2000; 32: 1189-95.
39. Angus PW, Patterson S.J. Liver transplantation for hepatitis B: what is the best hepatitis B immune globulin/ antiviral regimen? Liver Transpl 2008; 14: S15-22.
40. Neff GW, O'brien CB, Nery J, et al. Outcomes in liver transplant recipients with hepatitis B virus: resistance and recurrence patterns from a large transplant center over the last decade. Liver Transpl 2004; 10: 1372-8.
41. McGory RW, Ishitani MB, Oliveira WM, et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation 1996; 61: 1358-64.
42. Sawyer RG, McGory RW, Gaffey MJ, et al. Improved clinical outcomes with liver transplantation for hepatitis B-induced chronic liver failure using passive immunization. Ann Surg 1998; 227: 841-50.
43. Terrault NA, Zhou S, Combs C, et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 1996; 24: 1327-33.
44. Hooman N, Rifai K, Hadem J, et al. Antibody to hepatitis B surface antigen trough levels and half-lives do not differ after intravenous and intramuscular hepatitis B immunoglobulin administration after liver transplantation. Liver Transpl 2008; 14: 435-42.
45. van Hoek B, Kroes AC, Ringers J, et al. Switching intravenous to out-of-hospital fixed-dose intramuscular hepatitis B immunoglobulin after liver transplantation for HBsAg-positive HBV-DNA negative cirrhosis is feasible and reduces cost. Hepatology 2000; 32: 242A.
46. Hunt CM, McGill JM, Allen ML, Condreay L.D. Clinical relevance of hepatitis B virus mutations. Hepatology 2000; 31: 1037-44.
47. Loomba R, Rowley AK, Wesley R, et al. Hepatitis B immunoglobulin and lamivudine improve hepatitis Brelated outcomes after liver transplantation: meta-analysis. Clin Gastroenterol Hepatol 2008; 6: 696-700.
48. Mutimer D, Dusheiko G, Barrett C, et al. Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: long-term follow-up. Transplantation 2000; 70: 809-15.
49. Malkan G, Cattral MS, Humar A, et al. Lamivudine for hepatitis B in liver transplantation: a single-center experience. Transplantation 2000; 69: 1403-7.
50. Wai CT, Lim SG, Tan K.C. Outcome of lamivudine resistant hepatitis B virus infection in liver transplant recipients in Singapore. Gut 2001; 48: 581.
51. Fontana RJ, Keefe EB, Han S, et al. Prevention of recurrent hepatitis B infection following liver transplantation: experience in 112 North American patients. Hepatology 1999; 30: 301A.
52. Chan HL, Chui AK, Lau WY, et al. Outcome of lamivudine resistant hepatitis B virus mutant post-liver transplantation on lamivudine monoprophylaxis. Clin Transpl 2004; 18: 295-300.
53. Zheng S, Chen Y, Liang T, et al. Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B immunoglobulin prophylaxis. Liver Transpl 2006; 12: 253-8.
54. Katz L, Paul M, Guy D, et al. Prevention of recurrent hepatitis B virus infection after liver transplantation: HBIG, anti-viral drugs, or both? Systematic review and meta-analysis. Hepatology 2008; 48(Suppl.): 573A.
55. Karasu Z. Low-dose hepatitis B immune globulin and higher-dose lamivudine combination to prevent hepatitis B virus recurrence after liver transplantation. Antivir Ther 2004; 9: 921-7.
56. Ferretti G, Merli M, Ginanni CS, et al. Low-dose intramuscular hepatitis B immune globulin and lamivudine for long-term prophylaxis of hepatitis B recurrence after liver transplantation. Transpl Proc 2004; 36: 535-8.
57. Dumortier J, Chevallier P, Scoazec JY, et al. Combined lamivudine and hepatitis B immunoglobulin for the prevention of hepatitis B recurrence after liver transplantation: long-term results. Am J Transpl 2003; 3: 999-1002.
58. Sousa JM, Pareja F, Serrano J, et al. Comparison between levels of anti-HBS with a fixed administration dose of HBIG and a combination of HBIG and lamivudine for the prophylaxis of hepatitis B after liver transplantation. Transpl Proc 2003; 35: 723-4.
59. Anselmo DM, Ghobrial RM, Jung LC, et al. New era of liver transplantation for hepatitis B: a 17-year singlecenter experience. Ann Surg 2002; 235: 611-9.
60. Honaker MR, Shokouh-Amiri MH, Vera SR, et al. Evolving experience of hepatitis B virus prophylaxis in liver transplantation. Transpl Infect Dis 2002; 4: 137-43.
61. Steinmuller T, Seehofer D, Rayes N, et al. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology 2002; 35: 1528-35.
62. Seehofer D, Rayes N, Naumann U, et al. Preoperative antiviral treatment and postoperative prophylaxis in HBV-DNA positive patients undergoing liver transplantation. Transplantation 2001; 72: 1381-5.
63. Lee PH, Hu RH, Tsai MK, et al. Liver transplantation for patients with hepatitis B: prevention of hepatitis B recurrence by intravenous antihepatitis B immunoglobulin and lamivudine. Transpl Proc 2000; 32: 2245-7.
64. Han SH, Ofman J, Holt C, et al. An efficacy and costeffectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl 2000; 6: 741-8.
65. Angus PW, McCaughan GW, Gane EJ, et al. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl 2000; 6: 429-33.
66. McCaughan GW, Spencer J, Koorey D, et al. Lamivudine therapy in patients undergoing liver transplantation for hepatitis B virus precore mutant-associated infection: high resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose hepatitis B immune globulin. Liver Transpl Surg 1999; 5: 512-9.
67. Yoshida EM, Erb SR, Partovi N, et al. Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin. Liver Transpl Surg 1999; 5: 520-5.
68. Yao FY, Osorio RW, Roberts JP, et al. Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation. Liver Transpl Surg 1999; 5: 491-6.
69. Markowitz JS, Martin P, Conrad AJ, et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998; 28: 585-9.
70. Marzano A, Lampertico P, Mazzaferro V, et al. Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants. Liver Transpl 2005; 11: 532-8.
71. Karademir S, Astarcioglu H, Akarsu M, et al. Prophylactic use of low-dose, on-demand, intramuscular hepatitis B immunoglobulin and lamivudine after liver transplantation. Transpl Proc 2006; 38: 579-83.
72. Nath DS, Kalis A, Nelson S, et al. Hepatitis B prophylaxis post-liver transplant without maintenance hepatitis B immunoglobulin therapy. Clin Transpl 2006; 20: 206-10.
73. Gane EJ, Angus PW, Strasser S, et al. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology 2007; 132: 931-7.
74. Yoshida H, Kato T, Levi D. Lamivudine monoprophylaxis for liver transplant recipients with non-replicating hepatitis B virus infection. Clin Transplant 2007; 21: 166-71.
75. Jiao ZY, Jiao Z. Prophylaxis of recurrent hepatitis B in Chinese patients after liver transplantation using lamivudine combined with hepatitis B immune globulin according to the titer of antibody to hepatitis B surface antigen. Transpl Proc 2007; 39: 1533-6.
76. Neff GW, Kemmer N, Kaiser TE, et al. Combination therapy in liver transplant recipients with hepatitis B virus without hepatitis B immune globulin. Dig Dis Sci 2007; 52: 2497-500.
77. Akyildiz M, Karasu Z, Zeytunlu M, et al. Adefovir dipivoxil therapy in liver transplant recipients for recurrence of hepatitis B virus infection despite lamivudine plus hepatitis B immunoglobulin prophylaxis. J Gastroenterol Hepatol 2007; 22: 2130-4.
78. Buti M, Mas A, Prieto M, et al. Adherence to lamivudine after an early withdrawal of hepatitis B immune globulin plays an important role in the long-term prevention of hepatitis B virus recurrence. Transplantation 2007; 84: 650-4.
79. Takaki A, Yagi T, Iwasaki Y, et al. Short-term high-dose followed by long-term low-dose hepatitis B immunoglobulin and lamivudine therapy prevented recurrent hepatitis B after liver transplantation. Transplantation 2007; 83: 231-3.
80. Freshwater DA, Dudley T, Cane P, Mutimer D.J. Viral persistence after liver transplantation for hepatitis B virus: a cross-sectional study. Transplantation 2008; 85: 1105-11.
81. Yilmaz N, Shiffman ML, Todd SR, et al. Prophylaxis against recurrence of hepatitis B virus after liver transplantation: a retrospective analysis spanning 20 years. Liver Int 2008; 28: 72-8.
82. Angus P, Patterson SJ, Strasser S, et al. A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplant hepatitis B prophylaxis. Hepatology 2008; 48: 1460-6.
83. Ahn S, Dodson SF, Cohen S.M. Oral antiviral therapy without long term maintenance hepatitis B immunoglobulin to prevent hepatitis B recurrence in liver transplant patients. J Hepatol 2008; 48(Suppl. 2): S73-4.
84. Giusto M, Gentilli F, Loria I, et al. Combined therapy with low dose hepatitis B immunoglobulin (HBIG) and lamivudine (LAM) in patients transplanted for HBV chronic liver disease: long term efficacy and costs. J Hepatol 2008; 48(Suppl. 2): S84.
85. Lok ASF, Han SB, Schiff ER, et al. HBV recurrence rate post-liver transplantation (OLT) and associated factors: results of the NIH-HBV-OLT study. Hepatology 2008; 48(Suppl.): 571A.
86. Lo CM, Liu CL, Lau GK, et al. Liver transplantation for chronic hepatitis B with lamivudine-resistant YMDD mutant using add-on adefovir dipivoxil plus lamivudine. Liver Transpl 2005; 11: 807-13.
87. Caccamo L, Romeo R, Rossi G, et al. No hepatitis recurrence using combination prophylaxis in HBV-positive liver transplant recipients with YMDD mutants. Transpl Int 2005; 18: 186-92.
88. Yang Y, Zhang Q, Cai CJ, et al. Prophylaxis of hepatitis B recurrence in post-liver transplantation patients with lamivudine-resistant YMDD mutant. Chin Med J 2007; 120: 1400-3.
89. Osborn MK, Han SH, Regev A, et al. Outcomes of patients with hepatitis B who developed antiviral resistance while on the liver transplant waiting list. Clin Gastroenterol Hepatol 2007; 5: 1454-61.
90. Villet S, Pichoud C, Villeneuve JP, et al. Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient. Gastroenterology 2006; 131: 1253-61.
91. Terrault NA,Wright T.L. Combined short-term hepatitis B immunoglobulin (HBIG) and long-term lamivudine (LAM) versus HBIG monotherapy as hepatitis B virus (HBV) prophylaxis in liver transplant recipients. Hepatology 1998; 28: 389A.
92. Buti M, Mas A, Prieto M, et al. A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation. J Hepatol 2003; 38: 811-7.
93. Naoumov NV, Lopes AR, Burra P, et al. Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation. J Hepatol 2001; 34: 888-94.
94. Dodson SF, de Vera ME, Bonham CA, et al. Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation. Liver Transpl 2000; 6: 434-9.
95. Wong SN, Chu CJ, Wai CT, et al. Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy. Liver Transpl 2007; 13: 374-81.
96. Gane EJ, Strasser S, Patterson SJ, et al. A prospective study on the safety and efficacy of lamivudine and adefovir prophylaxis in HBsAg positive liver transplantation candidates. Hepatology 2007; 46: 479A.
97. Lenci I, Tisone G, Di Paolo D, et al. Total and covalently closed circular DNA (cccDNA) detection in post-transplant liver biopsies of HBV-positive patients who underwent liver transplantation with undetectable viremia. Hepatology 2008; 48(Suppl.): 573A.
98. Sanchez-Fueyo A, Rimola A, Grande L, et al. Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: a new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation. Hepatology 2000; 31: 496-501.
99. Angelico M, Di Paolo D, Trinito MO, et al. Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis. Hepatology 2002; 35: 176-81.
100. Bienzle U, Gunther M, Neuhaus R, Neuhaus P. Successful hepatitis B vaccination in patients who underwent transplantation for hepatitis B virus-related cirrhosis: preliminary results. Liver Transpl 2002; 8: 562-4.
101. Di Paolo D, Lenci I, Trinito MO, et al. Extended doubledosage HBV vaccination after liver transplantation is ineffective, in the absence of lamivudine and prior washout of human Hepatitis B immunoglobulins. Dig Liver Dis 2006; 38: 749-54.
102. Lo CM, Liu CL, Chan SC, et al. Failure of hepatitis B vaccination in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B. J Hepatol 2005; 43: 283-7.
103. Angelico M, Di Paolo D, Lenci I, et al. One-year extended anti-HBV vaccination with MPL-adjuvanted vaccine combined with anti-HBs immunoglobulins in patients transplanted for HBV-related cirrhosis. Hepatology 2008; 48(Suppl.): 584A.
104. Takaki A, Yagi T, Iwasaki Y, et al. Low-dose hepatitis B immunoglobulin with lamivudine for post-transplantation hepatitis B virus reactivation and monthly hepatitis B vaccine application is reliable, cost-effective treatment strategies. Hepatology 2008; 48(Suppl.): 586A.
105. Perrillo R, Rakela J, Dienstag J, et al. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Lamivudine Transplant Group. Hepatology 1999; 29: 1581-6.
106. Seehofer D, Rayes N, Bechstein WO, et al. Therapy of recurrent hepatitis B infection after liver transplantation. A retrospective analysis of 200 liver transplantations based on hepatitis B associated liver diseases. Z Gastroenterol 2000; 38: 773-83.
107. Fontana RJ, Hann HW, Wright T, et al. A multicenter study of lamivudine treatment in 33 patients with hepatitis B after liver transplantation. Liver Transpl 2001; 7: 504-10.
108. Ben-Ari Z, Mor E, Shapira Z, Tur-Kaspa R. Long-term experience with lamivudine therapy for hepatitis B virus infection after liver transplantation. Liver Transpl 2001; 7: 113-7.
109. Rayes N, Seehofer D, Hopf U, et al. Comparison of famciclovir and lamivudine in the long-term treatment of hepatitis B infection after liver transplantation. Transplantation 2001; 71: 96-101.
110. Ben-Ari Z, Pappo O, Zemel R, et al. Association of lamivudine resistance in recurrent hepatitis B after liver transplantation with advanced hepatic fibrosis. Transplantation 1999; 68: 232-6.
111. Peters MG, Singer G, Howard T, et al. Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient: durable response after orthotopic liver transplantation on adefovir dipivoxil and hepatitis B immune globulin. Transplantation 1999; 68: 1912-4.
112. Beckebaum S. Efficacy of combined lamivudine and adefovir dipivoxil treatment for severe HBV graft reinfection after living donor liver transplantation. Clin Transpl 2003; 17: 554-9.
113. Akay S, Karasu Z, Akyildiz M, Tokat Y. Adefovir treatment in posttransplant hepatitis B virus infection resistant to lamivudine plus hepatitis B virus immunoglobulin. Transpl Proc 2004; 36: 2768-70.
114. Wai CT, Prabhakaran K,Wee A, et al. Adefovir dipivoxil as the rescue therapy for lamivudine-resistant hepatitis B post liver transplant. Transpl Proc 2004; 36: 2313-4.
115. Toniutto P, Fumo E, Caldato M, et al. Favourable outcome of adefovir-dipivoxil treatment in acute de novo hepatitis B after liver transplantation. Transplantation 2004; 77: 472-3.
116. Barcena R. Study on the efficacy and safety of adefovir dipivoxil treatment in post-liver transplant patients with hepatitis B virus infection and lamivudine-resistant hepatitis B virus. Transpl Proc 2005; 37: 3960-2.
117. Lilly L, Therapondos G, Mason AL, Burak K.W. Tenofovir is effective in suppressing HBV replication in liver transplant recipients with nucleos(t)ide resistant recurrent disease. Hepatology 2008; 48(Suppl.): 574A.
118. Kamar N, Milioto O, Alric L, et al. Entecavir therapy for adefovir-resistant hepatitis B virus infection in kidney and liver allograft recipients. Transplantation 2008; 86: 611-4.
119. Shakil OA, Lilly L, Angus P, et al. Entecavir significantly reduces viral load in liver transplant recipients failing lamivudine therapy for chronic hepatitis B infection. J Hepatol 2002; 36(Suppl. 1): 122.